Sedana Medical AB (SEDANA) AI Stock Analysis

• Market Cap: €1.05B
• Dividend Yield: N/A
• Average Volume (3M): 247.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 13.48%
• EPS Growth: 28.98%
• Country: SE
• Employees: 113
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 99,336,960
• 10 Day Avg. Volume: 186,290
• 30 Day Avg. Volume: 247,675
• PEG Ratio: 2.17
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 10.60
• P/FCF Ratio: -10.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: kr10.00 ▼(-4.40% Downside)

Sedana Medical AB's stock score is primarily impacted by its financial performance and technical analysis. The company faces profitability challenges and cash flow issues despite a strong balance sheet. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to negative earnings.

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.

How the Company Makes Money

Sedana Medical generates revenue through the sale of its medical devices, primarily the AnaConDa system, and related consumables. The company earns money from direct sales to hospitals and healthcare facilities, as well as through partnerships with distributors and medical supply companies. Key revenue streams include the initial sale of the AnaConDa device, ongoing sales of consumable products necessary for its operation, and potential licensing agreements for technology use. Additionally, Sedana Medical benefits from collaborations with healthcare institutions for clinical studies, which can also lead to increased product adoption and sales.

Sedana Medical AB Financial Statement Overview

Summary

Sedana Medical AB shows modest revenue growth but struggles with profitability, reflected in negative net profit and EBIT margins. The balance sheet is stable with low leverage, but cash flow challenges persist, impacting operational sustainability.

Income Statement

Sedana Medical AB shows a modest revenue growth rate of 4.64% in the TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit margins (-25.93%) and EBIT margins (-20.65%). The gross profit margin remains strong at 70.37%, suggesting efficient cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's balance sheet is relatively stable with a low debt-to-equity ratio of 0.0053, indicating minimal leverage and financial risk. However, the return on equity is negative (-5.40%), reflecting ongoing losses and challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a strong capital structure.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating cash flow and a declining free cash flow growth rate (-15.01%). The free cash flow to net income ratio is high at 4.59, indicating that while the company is generating cash relative to its net losses, it is still insufficient to cover operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	196.12M	178.75M	153.87M	122.86M	159.15M	141.77M
Gross Profit	138.02M	126.14M	108.98M	86.07M	106.71M	88.90M
EBITDA	-18.92M	-4.03M	-51.67M	-64.87M	-49.10M	-17.22M
Net Income	-50.85M	-10.67M	-59.61M	-73.51M	-57.97M	-27.14M
Balance Sheet
Total Assets	978.89M	1.02B	1.01B	1.08B	1.17B	600.10M
Cash, Cash Equivalents and Short-Term Investments	130.71M	193.96M	381.80M	607.74M	836.18M	376.17M
Total Debt	4.87M	5.92M	4.31M	8.74M	8.87M	8.29M
Total Liabilities	58.66M	61.17M	44.06M	52.43M	66.12M	49.00M
Stockholders Equity	920.23M	958.23M	970.00M	1.03B	1.10B	551.09M
Cash Flow
Free Cash Flow	-130.77M	-186.77M	-206.95M	-253.22M	-151.48M	-92.47M
Operating Cash Flow	-28.48M	-11.77M	-38.06M	-115.43M	-41.22M	-7.85M
Investing Cash Flow	-127.15M	-44.67M	-321.96M	-137.78M	-110.25M	-84.62M
Financing Cash Flow	-3.91M	-3.57M	-4.86M	-1.51M	605.07M	5.79M

Sedana Medical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 10.46 is below the 20-day moving average (MA) of 12.01, below the 50-day MA of 12.96, and below the 200-day MA of 13.40, indicating a bearish trend. The MACD of -0.70 indicates Positive momentum. The RSI at 33.22 is Neutral, neither overbought nor oversold. The STOCH value of 10.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	―	€1.11B	43.19	6.93%	―	-5.80%	-65.99%
PAX	―	$1.58B	142.11	2.64%	―	14.28%	-68.33%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSSD	―	kr1.44B	―	―	―	36.23%	63.14%
SEZI	―	$932.29M	-6.14	-36.55%	―	62.24%	21.16%
SEDANA	―	€1.05B	-25.90	-4.42%	―	13.48%	28.98%
INTEG.B	―	€183.05M	-5.61	-18.35%	―	-5.63%	-1373.99%

Sedana Medical AB Corporate Events

Sedana Medical Reports Improved Q3 Performance Amid Market Challenges

Sedana Medical AB reported a 4% increase in net sales for Q3 2025 compared to the same period in 2024, with a notable improvement in EBITDA performance despite market challenges. The company experienced improved cash flow from operations and a reduction in operating costs, although cash flow from investments remained negative due to ongoing registration preparation work in the USA. The financial results reflect Sedana Medical’s strategic focus on enhancing operational efficiency and expanding its market presence in the medtech and pharmaceutical sectors.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK12.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.

Sedana Medical Announces 2026 Nomination Committee Formation

Sedana Medical AB has announced the formation of its Nomination Committee for the 2026 Annual General Meeting, comprising members appointed by its three largest shareholders and the Chairman of the Board. This committee, representing 31.69% of the voting rights, will propose resolutions for the meeting, including board composition and auditor appointments, impacting the company’s governance and strategic direction.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK14.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.

Sedana Medical to Present Q3 2025 Interim Report

Sedana Medical AB is set to release its interim report for the third quarter of 2025 on October 24, with a presentation scheduled later that day. The company’s CEO, CFO, and CMO will present the report and address questions, highlighting its ongoing commitment to transparency and stakeholder engagement.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK14.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.